[MMV e-alert] Letter from the CEO – 2011 in review | MMVPosted: January 16, 2012
To welcome in the New Year, I would like to share an overview of MMV’s progress in 2011 and our plans for 2012.
It has been a busy year for us. We achieved two major successes: European Medicines Agency (EMA) approval of Eurartesim® (dihydroartemisinin -piperaquine) developed jointly by MMV and Sigma-Tau and approval, by the Korean FDA, of Pyramax® (pyronaridine-artesunate), co-developed with Shin Poong. Pyramax, too, is currently being reviewed by the EMA.
Several potential antimalarial compounds progressed through the pipeline. The leading one, the synthetic peroxide, OZ439, completed Phase 1 of clinical development and has moved into Phase 2a. Preliminary results for the phase 2a study presented at ASTMH showed that the compound is not only potent but also holds promise as a much sought after one-dose cure for P.vivax and P.falciparum infection.